Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1 - Test2 - elhamkhani - TriplyDB

Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1

Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1

http://www.wikidata.org/entity/Q24673555

about

CCR5 monoclonal antibodies for HIV-1 therapy Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection Monoclonal CCR5 antibody for treatment of people with HIV infection PRO 140 (a CCR5 monoclonal antibody) for treatment in people with HIV infection Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors Maraviroc: a review of its use in HIV infection and beyond Access denied? The status of co-receptor inhibition to counter HIV entry Closing the door to human immunodeficiency virus.Progress towards recombinant anti-infective antibodies.Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody.Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults.Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases Synergistic combinations of the CCR5 inhibitor VCH-286 with other classes of HIV-1 inhibitors.Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate.The critical need for alternative antiretroviral formulations, and obstacles to their development.Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding site Antiretroviral drugs: critical issues and recent advances Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugs New approaches in the treatment of HIV/AIDS - focus on maraviroc and other CCR5 antagonists Monoclonal antibodies for prophylaxis and therapy of infectious diseases.Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211.Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc.Maraviroc: a new CCR5 antagonist.Maraviroc in the treatment of HIV infection.Antibody epitopes on g protein-coupled receptors mapped with genetically encoded photoactivatable cross-linkers.Immunotherapeutic restoration in HIV-infected individuals.HIV microbicides: state-of-the-art and new perspectives on the development of entry inhibitors.Complex interplay of kinetic factors governs the synergistic properties of HIV-1 entry inhibitors.Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients.Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention Universal antiretroviral regimens: thinking beyond one-pill-once-a-day.Opportunities for therapeutic antibodies directed at G-protein-coupled receptors.Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry.Combination of the CCL5-derived peptide R4.0 with different HIV-1 blockers reveals wide target compatibility and synergic cobinding to CCR5 Parenteral antiretroviral formulations are still urgently needed: a case report and commentary.Dual binding of an antibody and a small molecule increases the stability of TERRA G-quadruplex.Dual Binding of an Antibody and a Small Molecule Increases the Stability of TERRA G-Quadruplex.Synergistic efficacy of adapalene 0.1%-benzoyl peroxide 2.5% in the treatment of 3855 acne vulgaris patients.

P2860

Q22242739-BB0AE1FF-A5DE-41DE-9A1D-70769A005CAD Q24194805-12F5737B-C9B4-4AEA-B37F-0C57ACCF1502 Q24235689-2003C511-085D-4BB8-9FF2-9729E2683833 Q24239870-4730712B-B116-4D46-8197-14A6AC3AA578 Q24655129-809A33AE-A65C-4C61-AC3E-9B0B1FD999ED Q26778504-E072CA95-0C42-4FF4-945B-E8AB78B2FFE1 Q28300187-BF6FD0D6-BB5F-4F7F-B09A-5E5C5D213698 Q30428089-744BD34A-AD8C-4AE2-AF16-8D3860C41DE1 Q33568256-E712A4A5-1099-4744-8F2C-3A46F7112003 Q33798442-612AD090-ECDA-469C-B658-416DC40566F7 Q34150882-FEE8BFC8-9C27-41D6-8E29-556E1D74673E Q34536782-CCFF3031-C2DD-412D-B14D-02E97A1A464C Q34597465-B39AB8F9-7E5D-46ED-ACE1-F5BA3B6DC9B2 Q34757951-1B9728B3-7577-4A58-A8CB-3096F59F3B41 Q35164438-40907141-1DD4-4A23-A067-15E267C02288 Q35192937-5DA3F9C4-4B9E-4769-9A52-ED55C4F3F063 Q36020992-4B10447C-A33E-4D93-B58E-AFB5C18F89EF Q36703042-9CD0C2C6-4F9C-4DEF-B681-5A7BAEF54FAC Q36823525-D4F99753-98E1-402A-8D50-CA2230E0AD59 Q36989900-3B8B0CD0-DF6F-4868-88D5-A44DE1D2F4BD Q37373656-0E490FC8-DAF3-4B7A-BA8B-11597D4F81A5 Q37421895-3CA229F9-1788-4097-8147-426F7A3D301E Q37557671-C7935505-83CC-46B8-958E-960120108843 Q37634319-1B3A12F1-5FD1-435B-B874-633C3E38E304 Q37701720-9885B621-97D2-45D4-953D-29A36F736ADF Q37842335-AB77F60C-DF67-4D56-8FFF-644AD414DF41 Q37855900-3A3075B5-C813-44A4-A54F-2F09209E4536 Q38684463-21317BA8-C553-4F72-B10A-4ED39B3B7048 Q39098346-024D23DE-3733-4EC8-A701-034DF5670D5A Q39157923-CD29CC1D-CFD5-47DE-9057-D03E6C75A8CE Q39161979-FA3E419A-1816-4A34-AEA4-29B198ED65C2 Q39215169-F41FA69F-7303-417D-AB5A-A4B0BC18FDB7 Q39433833-94D33D53-2112-496D-ADD5-8EF8C09B89BE Q39454698-0CDDB0DA-06DF-4C8E-8243-6A37B07D04B6 Q41895256-448DF083-513A-4F8B-87F6-691AE0AB1FC7 Q41897622-95A96CC2-DF7C-48E9-9E42-30EEBB28A444 Q42212544-4C465D55-16CF-4C72-A290-5F228CA5BA93 Q42354421-736AF18F-B4EA-4E6F-B183-1B98089A865E Q42525813-18D08B4B-5971-4639-9168-4B9FE64F1175 Q45948374-76CC1325-C3C6-44A1-AF14-752D956E7A0F

P2860

Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1

http://www.wikidata.org/entity/Q24673555

description

2006 nî lūn-bûn

@nan

2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Potent antiviral synergy betwe ...... immunodeficiency virus type 1

@ast

Potent antiviral synergy betwe ...... immunodeficiency virus type 1

@en

Potent antiviral synergy betwe ...... immunodeficiency virus type 1

@nl

type

label

Potent antiviral synergy betwe ...... immunodeficiency virus type 1

@ast

Potent antiviral synergy betwe ...... immunodeficiency virus type 1

@en

Potent antiviral synergy betwe ...... immunodeficiency virus type 1

@nl

prefLabel

Potent antiviral synergy betwe ...... immunodeficiency virus type 1

@ast

Potent antiviral synergy betwe ...... immunodeficiency virus type 1

@en

Potent antiviral synergy betwe ...... immunodeficiency virus type 1

@nl

P1433

Q24673555-6F02DFC9-797A-4742-BE4B-3ADA85569683

P1476

Q24673555-B5B312D1-1C9C-48D9-9606-AC3B0B2A6BBF

P2093

Q24673555-39B9ACE2-157D-46C9-AF5A-3B2E50E7EAB5

Q24673555-75D52DE8-865F-41C6-9880-70D1A6D5DD41

Q24673555-826491C5-0361-4E5D-A9CC-016374369BF9

Q24673555-B78B6A55-5929-4146-9203-D87426BD00E7

Q24673555-B8FA2A87-E9A0-4B02-A618-D933A6E6CF5B

P2860

Q24673555-0011C999-27BC-4033-ADAD-040C29B2E9EA

Q24673555-04333E02-4B33-4E5E-8695-579836B40CB9

Q24673555-04871A79-6683-4047-AB9C-65CB08B305BE

Q24673555-077997D2-45B1-4BF0-9FA6-C815DC24C497

Q24673555-0BAF17FE-B4ED-490A-ACF9-D3DC329B07EC

Q24673555-0CD3EF37-40F2-4EE2-84A8-302569B1FBBA

Q24673555-10BC22BD-5F39-4D8A-8084-005C729B6325

Q24673555-2085FB36-23BF-47B0-834B-88CB8A171430

Q24673555-21669F9E-DEDA-4B58-B4C3-FB7313808ABD

Q24673555-24D9E362-0B08-4D98-B74D-30B1F336FC8B

P304

Q24673555-DD15CAC2-A21D-44C4-BA04-D13D222E762F

P31

Q24673555-F57B69F9-E098-4A6A-94B6-8C53E6E3A4A1

P356

Q24673555-0A4DE92A-060E-4196-B259-388FE9289D14

P407

Q24673555-28DA8C95-9CBB-4103-AA68-AD0D04469DF9

P433

Q24673555-47943E83-D060-4B63-9820-8FA06666453C

P478

Q24673555-CB0A66F6-F7A9-4E2D-9A46-FF495B0947F5

P577

Q24673555-CD18781A-1792-4B94-8484-85863D4F2C1A

P698

Q24673555-14B7275F-557E-4521-9F01-18F28AE37FDA

P921

Q24673555-63601187-C303-4764-A1CF-C57EFD801B27

Q24673555-6D38B8F2-5AFA-4668-B4E7-0D7CEF584CB0

P932

Q24673555-7D252943-9242-4F21-B00B-52C9F2DF524A

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Potent antiviral synergy betwe ...... immunodeficiency virus type 1

@en

P2093

Daniel C Pevear

http://www.w3.org/2001/XMLSchema#string

Jose D Murga

http://www.w3.org/2001/XMLSchema#string

Michael Franti

http://www.w3.org/2001/XMLSchema#string

Paul J Maddon

http://www.w3.org/2001/XMLSchema#string

William C Olson

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of a major co-receptor for primary isolates of HIV-1

TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro.

Spontaneous and antigen-induced production of HIV-inhibitory beta-chemokines are associated with AIDS-free status

Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a potent, highl

A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition

Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro

A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity

A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5

Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140

CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1

P304

3289-96

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00699-06

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P577

2006-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17005807

http://www.w3.org/2001/XMLSchema#string

P921

P932

1610098

http://www.w3.org/2001/XMLSchema#string